AIM IMMUNOTECH INC. Sale Leaseback Transaction, Transaction Costs, Financing Activities
AIM IMMUNOTECH INC. (AIM) reported Sale Leaseback Transaction, Transaction Costs, Financing Activities of $268.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:SaleLeasebackTransactionTransactionCostsFinancingActivities · last filed 2018-08-14
- AIM IMMUNOTECH INC. sale leaseback transaction, transaction costs, financing activities for the quarter ending 2018-06-30 was $0.00.
- AIM IMMUNOTECH INC. sale leaseback transaction, transaction costs, financing activities for the quarter ending 2018-03-31 was $268.00K.
| Period end | Sale Leaseback Transaction, Transaction Costs, Financing Activities 3 month | Sale Leaseback Transaction, Transaction Costs, Financing Activities 6 month |
|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $268.00K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $268.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |